Literature DB >> 1348538

Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo.

K V Speeg1, A L Maldonado, J Liaci, D Muirhead.   

Abstract

The multidrug resistance (MDR) transport protein is a normal constituent of proximal renal tubules although its function has not been defined in vivo. We find that colchicine, an MDR substrate, is secreted into urine by a process which is distinct from the organic cation transporter responsible for tetraethylammonium and N-methylnicotinamide secretion. Cyclosporine (CsA), which reverses MDR in vitro presumably by inhibiting the MDR transporter, inhibits colchicine renal secretion but does not inhibit the net secretion of the organic cation, ranitidine, or the organic anion, p-aminohippurate. After CsA (2 mg/kg i.v.), colchicine renal clearance decreased from 6.23 +/- 0.46 to 3.58 +/- 0.31 ml/min.kg (P less than .05), glomerular filtration rate was unchanged (4.21 +/- 0.08 and 3.88 +/- 0.17 ml/min.kg, before and after CsA, respectively; P = .09) and colchicine secretory ratio decreased from 1.48 +/- 0.11 to 0.92 +/- 0.07 (P less than .05). Cremophor (CsA vehicle) increased colchicine renal clearance (6.77 +/- 0.29 to 7.7 +/- 0.3 ml/min.kg, P less than .05) and colchicine secretory ratio (1.425 +/- 0.071 to 1.621 +/- 0.061, P less than .05). The inhibition of colchicine secretion was long-lived lasting at least 30 hr after CsA. Thus, colchicine is actively secreted into urine by the multidrug transporter in vivo. CsA profoundly inhibits colchicine secretion into urine while having no effect on the secretion of the organic cation ranitidine or the organic anion p-aminohippurate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348538

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions.

Authors:  Matthew W Davis; Suman Wason
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

3.  Membrane Assays to Characterize Interaction of Drugs with ABCB1.

Authors:  Zsolt Fekete; Zsuzsanna Rajnai; Tünde Nagy; Katalin Tauberné Jakab; Anita Kurunczi; Katalin Gémes; Krisztina Herédi-Szabó; Ferenc Fülöp; Gábor K Tóth; Maciej Czerwinski; Greg Loewen; Peter Krajcsi
Journal:  J Membr Biol       Date:  2015-04-30       Impact factor: 1.843

4.  Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine.

Authors:  Elaine Tseng; Amrita Kamath; Marilyn E Morris
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 5.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

6.  Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

7.  Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells.

Authors:  Shuzhong Zhang; Marilyn E Morris
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

8.  P-glycoprotein is more efficient at limiting uptake than inducing efflux of colchicine and vinblastine in HL-60 cells.

Authors:  X Declèves; O Chappey; B Boval; E Niel; J M Scherrmann
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

9.  Effect of cyclosporine on colchicine partitioning in the rat liver.

Authors:  K V Speeg; A L Maldonado
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 10.  Colchicine: its mechanism of action and efficacy in crystal-induced inflammation.

Authors:  George Nuki
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.